Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7815927 | 0.88 | CYP3A4 (0.35) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7617860 | 0.88 | CYP3A4 (0.36) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7812729 | 0.86 | CYP3A4 (0.36) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7812726 | 0.83 | CYP3A4 (0.35) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7609931 | 0.81 | CTSL (0.43) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7461611 | 0.80 | CTSL (0.47) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7819709 | 0.76 | CTSL (0.43) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7617864 | 0.75 | CTSL (0.43) | CTSLCTSBCTSSCTSKKDM4E | |
| SCHEMBL7609369 | 0.74 | CTSL (0.37) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL7611777 | 0.74 | CTSK (0.35) | CTSLCTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | claimed |
| EP-1068304-A4 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORP (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1068304-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1068304-A4 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORP (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1068304-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSL 22/4885CTSB 35/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.